HQH: After Biotech's Breakout Year, This Healthcare CEF Still Trades Below NAV; Buy
· seekingalpha.com
Abrdn Healthcare Investors biotech CEF: 6.4% NAV discount, 56% NAV gain, 12% gain-funded payout, key risks. Read my analysis here on HQH.
I focus on a rigorous fundamentals-foremost equity and credit research. I currently work as a financial advisor/planner, and do analysis in my free time. I have...